The gene encoding DCC is frequently deleted in cancer (Arakawa, 2004), and Netrin-1 blocking antibodies are in Phase II clinical trials for endometrial and cervical carcinomas to inhibit metastatic growth (Brisset et al., 2021). Here, NTN1 is linked to cancer.